Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Trial of S227928 ± Venetoclax in R/R AML, MDS/AML, or CMML
2024-514356-33-00Phase 2Completed
- Sponsor
- Servier
- Start
- Feb 2025
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 2, open-label trial of S227928 and venetoclax in acute myeloid leukemia (AML), myelodysplastic/myeloproliferative neoplasm (MDS/MPN), myelodysplastic syndrome (MDS) and 1 more (2 arms), sponsored by Servier. Primary endpoints: Incidence and severity of dose-limiting toxicities (DLTs) of S227928 as a single agent and combined with venetoclax during the first cycle of treatment, Incidence of adverse events (AEs) and serious adverse events (SAEs) and 3 more. Started Feb 2025; status: completed.
02
Drugs
S227928venetoclax
03
Conditions
acute myeloid leukemia (AML)myelodysplastic/myeloproliferative neoplasm (MDS/MPN)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on 2024-514356-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514356-33-00.